Prosecution Insights
Last updated: November 20, 2026
Application No. 19/034,970

Drug For Treating Disorders Of An Organ Or Tissue Function And Diseases Accompanied By Such Disorders, And The Method For Obtaining It

Non-Final OA §103§112
Filed
Jan 23, 2025
Priority
May 22, 2018 — RU 2018118695 +2 more
Examiner
PALENIK, JEFFREY T
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Oleg Iliich Epshtein
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
1y 6m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
479 granted / 895 resolved
-6.5% vs TC avg
Strong +27% interview lift
Without
With
+27.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
59 currently pending
Career history
955
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
48.4%
+8.4% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
19.1%
-20.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 895 resolved cases

Office Action

§103 §112
DETAILED ACTION Status of the Application Receipt is acknowledged of Applicants’ Preliminary Amendments and Remarks, filed 23 January 2025, in the matter of Application N° 19/034,970. Said documents have been entered on the record. The Examiner further acknowledges the following: The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-66 have been canceled. Claims 67-76 have been added and are supported by the originally-filed disclosure. None of the newly added claims have been amended. No new matter has been added. Thus, claims 67-76 now represent all claims currently under consideration. Priority Acknowledgment is made of Applicants’ claim for foreign priority under 35 U.S.C. 119 (a)-(d). The certified copy has been filed in parent Application No. 17/057,624, filed on 29 April 2019. Should Applicants desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Information Disclosure Statement No Information Disclosure Statements (IDS) have been filed for consideration. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP §609.04(a) states, “the list may not be incorporated into the specification but must be submitted in a separate paper.” Therefore, unless the references have been cited by the Examiner on form PTO-892, they have not been considered. Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicants are required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP §608.01. Claim Objections Claim 67 is objected to because of the following informalities: the claim uses a traditional symbol of mathematical division “ PNG media_image1.png 18 18 media_image1.png Greyscale ”, to symbolize a recited range. See lines 11-12 and line 23 of claim 67; the limitation reciting “wherein an electric current is applied to said release-active form of the drug” (lines 14-15) appears to be a duplicated step to that which is recited in line 10 of the claim; and the phrase “used either individually;” (line 9) is duplicative and can be removed. Claim 70 is objected because the language “…bioelectric potentials are taken reading by using …” is grammatically incorrect. Claim 73 is objected because the language “…bioelectric potentials are taken reading by…” is grammatically incorrect. Appropriate corrections are required. Claim Rejections - 35 USC §112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 67-76 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 67 recites the limitations “the medicament” in line of the claim and “the drug substance stock (matrix) solution” in lines 3-4 of the claim. There is insufficient antecedent basis for these limitations in the claim. Additionally, regarding claim 67, the phrase “such disorders” (line 2) renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP §2173.05(d). The limitation reciting “for treating disorders of functions of organs or tissues or diseases accompanied by such disorders” renders the claim indefinite since it is unclear exactly what disorder is intended to be treated. [emphasis added] The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 69 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The claim, which depends directly from independent claim 67, recites “wherein the external treatment – mechanical shaking of every dilution”. This limitation is already presented in claim 67 (see lines 12-13), and therefore fails to further limit the recited invention. Applicants may cancel the claim, amend the claim to place the claim in proper dependent form, rewrite the claim in independent form, or present a sufficient showing that the dependent claim complies with the statutory requirements. Claim Rejections - 35 USC §103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the Examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicants are advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the Examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 67-76 are rejected under 35 U.S.C. 103 as being unpatentable over Epshtein (US Pre-Grant Publication Nº 2017/0333560 A1; herein referred to as “Epshtein (2017)”) in view of Epshtein (US Pre-Grant Publication Nº 2013/0058982 A1; herein referred to as “Epshtein (2013)”). With respect to independent claim 67, Epshtein (2017) discloses a medicament, wherein the medicament comprises a release-active form of a drug substance obtained by successive multiple (serial) dilutions of a drug substance stock (matrix) solution, combined with external treatment of each serial dilution, in particular by mechanical shaking. The release active form of the drug substance is also taught as being treated by passing an electric current wherein the electric current is applied to at least two electrodes immersed in the release-active form of the drug substance and wherein the electric current is proportional to bioelectric potentials measurements obtained. The reference also discloses that the potential difference applied to the electrodes immersed in the release active form of drug substance is proportional in amplitude to the amplified resultant signal produced by the summing of the bioelectric potential measurements obtained by the electrophysiological method on the normal functioning organs or tissues. See ¶[0006] and ¶[0104]. Bioelectric potentials are also taught as being measured from tissues of healthy donors. See e.g., ¶[0036]. Epshtein (2017) also discloses the bioelectric potentials are input to channel amplifier where the peak amplitude of the output signal being between 0.5 +/- volts the amplified bioelectric potentials are based through a low-pass filter with a bandwidth of 0.5 to 35 Hz, thus meeting the limitations of claim 67 and 69. See ¶[0078]-¶[0080] and claims 88-91. Epshtein (2017) is deficient with respect to claim 67 on two points. First, the reference does not expressly disclose the recited drug substance (matrix) stock solution concentration of 0.5-10 mg/mL. Secondly, the reference does not expressly disclose the instantly recited drug substances. Regarding the former, the Examiner advances that Epshtein (2017) need not necessarily disclose the starting concentration for the drug substance stock (matrix) solution(s), notably as the reference does expressly disclose subjecting the matrix solution to serial dilution. Stated another way, the instantly claimed method does not recite what the concentration of the prepared (diluted and shaken) drug solution will ultimately be; it only recites what the starting point might be. As such, the initial stock solution concentration is not considered to be definitive of the claimed method, since the recited method departs from the starting concentration. However, regarding both deficiencies, Epshtein (2013) discloses activated-potentiated forms of antibodies to brain-specific protein S-100 and activated-potentiated forms of antibodies to endothelial NO synthase. See e.g., Abstract; ¶[0012]. Paragraph [0021] further defines “activated-potentiated form” as being prepared from a stock solution having a starting concentration ranging from about 0.5 to about 5.0 mg/mL and preferably being diluted in a water or water-ethyl alcohol mixture. The procedure for the drug substance also includes vertical (mechanical) shaking following the dilution steps. The preferred activated-potentiated form of the prepared drug substance will be an antibody to protein S-100 as a monoclonal, polyclonal, or a natural antibody. See e.g., ¶[0016]. Based on the combined guidance provided the references, the Examiner submits that a person of ordinary skill in the art, would have had a reasonable expectation of success in devising the instantly claimed preparation method by modifying the method of Epshtein (2017) to prepare a drug substance disclosed by Epshtein (2013). The key similarity shared by the two references is that they employ the same method of preparing their respective drug solutions. The key distinction between the two teachings is that Epshtein (2017) simply does not specifically identify the substances prepared, referring to said substance as the “AP drug”. Modifying Epshtein (2017) to incorporate specific actives as disclosed by Epshtein (2013) would present the skilled artisan with the expectation of meeting the limitations of instant claims 67 and 69. Further motivation is taken from Epshtein (2017) at ¶[0025] where disorders to be treated are discussed as including cerebrovascular diseases/chronic vascular disorders of the brain, dementia in Alzheimer’s disease, and dementia in other diseases. Epshtein (2013) is directed to methods for treating Alzheimer’s disease, thereby lending guidance to the drug substances relied upon by the reference. With respect to claim 68, Epshtein (2017) discloses the treated release active form of the drug substance is subjected to successive multiple dilutions in a solvent selected from the group comprising water and a mixture of water and ethanol, complemented by external treatment, thus meeting the limitations of claim 68. See e.g., Abstract; ¶[0006]. The reference also discloses that bioelectric potentials (or biopotentials) are obtained by electroencephalography (EEG), thereby meeting the limitations recited by instant claims 70, 72, and 73 (see e.g., Abstract; ¶[0006]). Lastly, regarding the limitations recited by each of claims 71 and 74-76, ¶[0078] discloses that “[p]referably, the differences of biopotential are initially recorded in referential derivations by recording electrodes that contribute to separate channels from different locations on the scalp and are referenced to a zero potential point (underlying the reference electrode) on the ear-lobe, following which they are amplified separately in each channel, the amplified outputs being then digitized and the resulting digitized and digitally filed signals are transferred into the memory of a programmable digital signal summing unit—a signal summer, where the digital signals are added up to produce a summed digital signal representing the overall (summed) potential difference of the referential derivations employed, which is thereafter inputted to a digital-to-analog converter of an arbitrary waveform generator, where it is converted back to a summed analog signal to generate output signals in the form of voltages (potential difference) which approximate the waveform of the summed difference of bioelectric potentials recorded, and are fed onto at least two current electrodes immersed in the container with the initial neutral carrier.” Based on the combined teachings of the references, the Examiner submits that a person of ordinary skill in the art would have had a reasonable expectation of success at devising the instantly claimed method of treatment. Therefore, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, and absent a clear showing of evidence to the contrary. All claims have been rejected; no claims are allowed. Correspondence Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jeffrey T. Palenik whose telephone number is (571) 270-1966. The Examiner can normally be reached on 9:30 am - 7:00 pm; M-F (EST). If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Jeffrey T. Palenik/ Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Jan 23, 2025
Application Filed
Nov 12, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797508
FLUORAPATITE-CONTAINING STRUCTURES STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
5y 4m to grant Granted Nov 17, 2026
Patent 12797335
TRIMODAL, PRECISION-TIMED RELEASE TABLET
2y 3m to grant Granted Nov 17, 2026
Patent 12788033
Drinking Formulation for Maintaining Urinary Tract Health in Cats
2y 0m to grant Granted Nov 10, 2026
Patent 12778900
DELMOPINOL AND DELMOPINOL SALT CONTAINING NANOPARTICLES AND USES THEREOF
2y 1m to grant Granted Nov 03, 2026
Patent 12766093
COLLOIDAL SILVER COMBINED WITH PLANT EXTRACTS FOR USE IN TREATING WOUNDS AND OTHER SKIN CONDITIONS
2y 0m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
81%
With Interview (+27.1%)
3y 4m (~1y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 895 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month